The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
The FDA on Monday approved nirsevimab, a single shot of antibodies that was shown in clinical trials to lower the need for medical care from RSV for babies by 70-75%.
DTx Pharma focuses on developing therapies targeting disorders affecting the nervous system, which aligns with Novartis’ efforts to expand its neuroscience pipeline.
The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.
Americans will soon be able to grab an over-the-counter treatment for heavy periods, cramps, headaches, and migraines; they’ll have prescription-free access to a drug for endometriosis and polycystic ovary syndrome; and they’ll be able to buy a medication that can mitigate the symptoms of menopause.